Protagenic Therapeutics Inc (PTIX)
1.44
-0.06
(-4.01%)
USD |
NASDAQ |
May 20, 16:00
Protagenic Therapeutics Enterprise Value: 2.330M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 2.330M |
| May 17, 2024 | 2.597M |
| May 16, 2024 | 2.552M |
| May 15, 2024 | 2.107M |
| May 14, 2024 | 1.488M |
| May 13, 2024 | 1.910M |
| May 10, 2024 | 1.910M |
| May 09, 2024 | 1.665M |
| May 08, 2024 | 1.448M |
| May 07, 2024 | 1.355M |
| May 06, 2024 | 1.488M |
| May 03, 2024 | 1.621M |
| May 02, 2024 | 2.042M |
| May 01, 2024 | 1.710M |
| April 30, 2024 | 2.050M |
| April 29, 2024 | 2.198M |
| April 26, 2024 | 2.087M |
| April 25, 2024 | 2.901M |
| April 24, 2024 | 3.209M |
| April 23, 2024 | 2.907M |
| April 22, 2024 | 1.488M |
| April 19, 2024 | 1.665M |
| April 18, 2024 | 2.020M |
| April 17, 2024 | 1.931M |
| April 16, 2024 | 1.931M |
| Date | Value |
|---|---|
| April 15, 2024 | 2.141M |
| April 12, 2024 | 2.330M |
| April 11, 2024 | 3.218M |
| April 10, 2024 | 3.173M |
| April 09, 2024 | 2.885M |
| April 08, 2024 | 2.730M |
| April 05, 2024 | 3.084M |
| April 04, 2024 | 3.262M |
| April 03, 2024 | 3.218M |
| April 02, 2024 | 3.439M |
| April 01, 2024 | 3.661M |
| March 28, 2024 | 3.705M |
| March 27, 2024 | 4.016M |
| March 26, 2024 | 3.705M |
| March 25, 2024 | 3.669M |
| March 22, 2024 | 2.818M |
| March 21, 2024 | 2.286M |
| March 20, 2024 | 1.931M |
| March 19, 2024 | 1.687M |
| March 18, 2024 | 1.266M |
| March 15, 2024 | 1.044M |
| March 14, 2024 | 0.8226M |
| March 13, 2024 | 0.8669M |
| March 12, 2024 | 0.4234M |
| March 11, 2024 | 0.9557M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-1.784M
Minimum
Dec 29 2022
73.23M
Maximum
Mar 02 2021
12.18M
Average
4.447M
Median
May 03 2022
Enterprise Value Benchmarks
| Ekso Bionics Holdings Inc | 20.67M |
| Eyenovia Inc | 46.80M |
| Palisade Bio Inc | -5.789M |
| NovaBay Pharmaceuticals Inc | 7.267M |
| Palatin Technologies Inc | 22.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.676M |
| Total Expenses (Quarterly) | 1.212M |
| EPS Diluted (Quarterly) | -0.38 |
| Earnings Yield | -79.86% |